Moreover, Civallero et al. have demonstrated the antitumor activity of ruxolitinib and vorinostat®, another HDAC inhibitor, in cell lines of hematologic malignancies, including Hodgkin’s lymphoma and selected subtypes of non-Hodgkin’s lymphoma, multiple myeloma and CTCL [35]. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.